Irinotecan monotherapy

DRUG2 trials

Sponsors

Third department of internal medicine, Universtiy of Fukui, Institut du Cancer de Montpellier - Val d'Aurelle

Conditions

Extensive stage small cell lung cancerMetastatic Colorectal Cancer Patients With KRAS Mutated Tumors

Phase 2

Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

CompletedNCT01715441

Institut du Cancer de Montpellier - Val d'AurelleMetastatic Colorectal Cancer Patients With KRAS Mutated Tumors

Start: 2012-09-01End: 2015-09-01Updated: 2026-02-05

Efficacy and safety of irinotecan after chemotherapy in combination with immunotherapy in patients with extensive stage small cell lung cancer: a phase II trial

Active, not recruitingJPRN-UMIN000042892

Third department of internal medicine, Universtiy of FukuiExtensive stage small cell lung cancer

Start: 2021-01-15Target: 22Updated: 2026-06-29

Related Papers

Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).

Journal of Clinical Oncology2016-05-201 citations

Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2).

Journal of Clinical Oncology2016-02-013 citations

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

British Journal of Cancer2014-01-0955 citations